The Smartest Investors Club
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Smartest Investors Club

Investing

Significant Uranium anomalies identified across the NT

by June 17, 2025
June 17, 2025
Significant Uranium anomalies identified across the NT

Greenvale Energy (GRV:AU) has announced Significant Uranium anomalies identified across the NT

Download the PDF here.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Crypto Market Recap: Whales Flock to Ethereum, Trump Media Eyes Bitcoin-Ether ETF
next post
Starbucks moves to the next phase in its turnaround: Winning over employees

You may also like

3 Key Themes from Fastmarkets’ 2025 Lithium Supply...

Biotech and Pharma Market Update: Q2 2025 in...

Homerun Resources Inc. Announces Receipt of a Competitive...

Dana Samuelson: Gold Heading to US$4,000, but Silver...

Ford Government Pushes Bill 5 Through Legislature, Sparking...

Asara Resources: Advancing the Next West African Gold...

Questcorp Mining Engages Marketing Consulting Firm Spark Newswire

Ericsson, Rogers Launch Canada’s First Underground 5G Network...

Carbonxt Increases Stake in Kentucky Facility

Thick zones of HM mineralisation observed across Douala...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Homerun Resources Inc. Receives Joint Support Plan from BNDES and FINEP Indicating...

    • Galan Lithium Limited: Incentive Regime for HMW Project in Argentina

    • Anteros Metals Initiates Channel Sampling at Havens Steady Following Grant Confirmation and Exploration Permit Approval

    • Allied Critical Metals Launches Allied USA to Expand Tungsten Import and Distribution Operations, Lists on OTCQB, and Receives DTC Eligibility

    • Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

    Categories

    • Business (70)
    • Investing (523)
    • Politics (700)
    • World (262)
    • Terms & Conditions
    • Privacy Policy
    • About us

    Disclaimer: thesmartestinvestorsclub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 thesmartestinvestorsclub.com | All Rights Reserved


    Back To Top